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A B S T R A C T
Rheumatoid arthritis (RA) is a destructive and chronic autoimmune inﬂammatory disease. Synovial in-
ﬂammation is a major feature of RA and is associated with leukocyte recruitment. Leukocytes cross the en-
dothelial cells (ECs) into the synovial tissue and ﬂuid and this migration is mediated via a range of chemokines
and adhesion molecules on the ECs. As important mediators of leukocyte extravasation, a number of chemokines
from each of the chemokine families have been established as expressed in the RA joint.
However, as little information is available on which chemokines are expressed/presented by the ECs them-
selves, the purpose of the study was to ascertain which of the CC chemokines were localised in RA ECs.
Immunoﬂuoresence was used to assess the presence of the CC-family chemokines in RA synovial ECs using
von-Willebrand factor (VWF) as a pan-endothelial marker and a range of human chemokine antibodies. The
percentage of VWF positive vessels which were positive for the chemokines was determined. The presence of the
four most highly expressed novel chemokines were further investigated in non-RA synovial ECs and the sera and
synovial ﬂuid (SF) from patients with RA and osteoarthritis (OA). Statistical analysis of immunoﬂuorescence
data was carried out by Student’s t-test. For analysis of ELISA data, Kruskal-Wallis ANOVA followed by Dunn’s
multiple comparison test was utilised to analyse diﬀerences in sera and SF levels for each chemokine between RA
and OA. Spearman rank correlations of sera and SF chemokine levels with a range of clinical variables were also
performed.
Chemokine detection varied, the least abundant being CCL27 which was present in 8.3% of RA blood vessels
and the most abundant being CCL19 which was present in 80%. Of the 26 chemokines studied, 19 have not been
previously observed in RA ECs. Four of these novel chemokines, namely CCL7, CCL14, CCL16 and CCL22 were
present on≥60% of vessels. CCL14 and CCL22 were shown to be increased in RA ECs compared to non-RA ECs,
p= 0.0041 and p= 0.014 respectively. EC chemokines CCL7, CCL14, CCL16 and CCL22 also occurred in RA
synovial ﬂuid and sera as established by ELISA. CCL7 was shown to be signiﬁcantly increased in sera and SF from
RA patients compared to that from osteoarthritis (OA) patients (p < 0.01), and to have a highly signiﬁcant
correlation with the level of anti-CCP (R = 0.93, p= 0.001). Less abundant chemokines shown to be present in
RA ECs were CCL1-3, CCL5, CCL10-13, CCL15, CCL17, CCL18, CCL20, CCL21 and CCL23-28.
In conclusion, this initial study is the ﬁrst to show the presence of a number of CC chemokines in RA ECs. It
provides evidence that further validation and investigation into the presence and functionality of these novel
chemokines expressed at RA synovial ECs may be warranted.
1. Introduction
There are currently around 48 chemokines grouped according to
structural criteria. Each is a single polypeptide chain of 70–100 amino
acid residues which share 20–95% sequence homology, including a
number of conserved cysteine residues. The cysteine residues have been
utilised in the nomenclature system and give four distinct chemokine
subgroups [1–3]: CC, CXC, C (or XC) and CX3C chemokines. These are
further split into:
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1. Inﬂammatory chemokines, such as CXCL8 and CCL2 which are
usually only expressed under inﬂammatory conditions, and as such
are found in high levels in the RA joint. Their production can be
induced in response to stimulation by pro-inﬂammatory cytokines
such as IL-1 and TNFα [4] and they are important mediators in the
recruitment of eﬀector cells of both the innate and adaptive immune
system.
2. Constitutive (homeostatic) chemokines, which are expressed con-
tinuously, and direct essential physiological processes such as hae-
matopoiesis [5], lymphocyte and dendritic cell homing [6,7] and
the normal immune surveillance of body tissues. Unlike in-
ﬂammatory chemokines they usually bind to speciﬁc single re-
ceptors [5].
3. Dual function chemokines, which are involved in normal immune
defense and are upregulated in inﬂammatory conditions. This group
includes CXCL9, CXCL10, CXCL11, CCL1, CCL20 and CCL25 [7,8].
Chemokines stimulate leukocyte recruitment into inﬂamed tissue.
These mediators are bound by ECs and presented to chemokine re-
ceptors on leukocytes in the blood leading to leukocyte extravasation
into the aﬀected tissue [9]. Much work has been undertaken on che-
mokines in RA [10]. They have been identiﬁed in synovial tissue, car-
tilage and SF, and are produced by cells such as macrophage and ﬁ-
broblasts. These chemokines are biologically active and stimulate
leukocyte migration. Blocking chemokines and their receptors in an-
imal models of RA have led to reduced severity of disease and sig-
niﬁcant therapeutic eﬀects. Thus, they have been favoured therapeutic
targets of the pharmaceutical and biotech industry with clinical trials
carried out using anti-chemokine antibodies and chemokine receptor
antagonists. Most of these agents did not show clinical eﬃcacy in
clinical trials in RA patients with little exception [11,12]. One reason
for the lack of success in clinical studies may be because many che-
mokines have been identiﬁed in RA joints and it can be problematic to
choose the most eﬀective ones to target. Our approach has been to try
and identify which chemokines are presented by ECs in RA. Therefore,
the main purpose of this study was to report on the presence of the CC-
family chemokines in ECs of the rheumatoid synovium, and to identify
any highly expressed chemokines which are found at signiﬁcantly
higher levels than in non-RA. We also wished to determine whether
highly expressed CC chemokines in the synovium were also present in
the sera and/or synovial ﬂuid, and whether they showed any re-
lationship with clinical variables. Diﬀering chemokine proﬁles for ar-
thritides may allow for the further identiﬁcation of potential disease
markers [13,14]. The current study compares CCL7, CCL14, CCL16 and
CCL22 in RA and OA SF and sera and analyses their correlations with
various clinical variables.
2. Materials and methods
2.1. Ethics
Ethical approval was obtained from the Birmingham and Solihull
Research Ethics Committee (reference 11/WM/0035) and patients
provided written informed consent.
2.2. Synovial tissue and sera
RA knee synovial tissue and SF were obtained from patients who
fulﬁlled the American College of Rheumatology (ACR) criteria for RA.
The patients were undergoing joint replacement surgery or synovial
eﬀusion removal at the Robert Jones and Agnes Hunt Orthopaedic
Hospital, Oswestry (n = 8). Patients had a mean age of 66 years and
mean disease duration of 23 years at the time of surgery.
Non-RA control tissue from knee joints (n = 6) was obtained by
needle biopsy during outpatient exploratory procedures where arthritis
had been excluded as a diagnosis. Histology of RA synovia showed
classic synovitis with lymphocyte and macrophage inﬁltration of the
sublining, and lining layer (intima). Non-RA synovia showed com-
paratively little or no leukocyte inﬁltration. Synovial tissue samples
were taken from the suprapatellar pouch and the medial gutter and
placed in Hank’s Balanced Salt Solution (HBSS) for transport to the
laboratory.
Paired RA SF and serum samples were taken from a further 17 RA
patients and 7 OA patients. A wide range of clinical variables were
assessed in these arthritis patients. These included erythrocyte sedi-
mentation rate (ESR), joint scores and disease activity scores (DAS44)
[15] to assess systemic inﬂammation and overall disease activity. Fur-
ther variables such as early morning stiﬀness (EMS), grip strength and
Health Assessment Questionnaire (HAQ) [16] were used to assess pain
and loss of function at the diﬀerent disease stages, while the amount of
joint damage was assessed by the damage scale of the Overall Status in
Rheumatoid Arthritis (OSRA) [17]. This has been correlated with ar-
ticular damage as determined by radiographs using the Larsen score.
2.2.1. Immunoﬂuorescence labelling of synovial tissue sections
Tissue samples were snap frozen in iso-pentane (cooled in liquid
nitrogen) and then stored in liquid nitrogen. 5–6 μm thick serial cryo-
stat sections of the tissue were cut then air dried at room temperature
before being stored at -80 °C. Sections were stained as previously de-
scribed [18]. Brieﬂy, sections were blocked then incubated for 1 h in
the primary antibodies, the working concentrations used were: anti-
human mouse monoclonal CCL2 (10 µg/ml; MAB2791), mouse mono-
clonal CCL3 (10 µg/ml; MAB270), goat polyclonal CCL4 (10 µg/ml; AF-
271-NA), goat polyclonal CCL5 (15 µg/ml; AF-278-NA), mouse mono-
clonal CCL11 (15 µg/ml; MAB320), goat polyclonal CCL16 (15 µg/ml;
AF802), goat polyclonal CCL17 (10 µg/ml; AF364), mouse monoclonal
CCL19 (20 µg/ml; MAB361), goat polyclonal CCL20 (10 µg/ml;
AF360), goat polyclonal CCL21(15 µg/ml; AF366), goat polyclonal C-
CL24 (15 µg/ml; AF343), goat polyclonal CCL26 (10 µg/ml; AF653),
mouse monoclonal CCL27 (20 µg/ml; MAB367), (all R & D Systems,
UK), goat polyclonal CCL8 (2 µg/ml; Sc-1307), goat polyclonal CCL13
(4 µg/ml; Sc-9655), mouse monoclonal CCL14 (2 µg/ml; Sc-28388),
goat polyclonal CCL18 (4 µg/ml; Sc-9781), goat polyclonal CCL22
(4 µg/ml; Sc-12285), goat polyclonal CCL23 (4 µg/ml; Sc-12263), goat
polyclonal CCL25 (2 µg/ml; Sc-12277) and goat polyclonal CCL28
(4 µg/ml; Sc-27339) (all SantaCruz Biotechnology Inc UK), mouse
monoclonal CCL1 (2.5 µg/ml; LS-C4342) and rabbit polyclonal CCL7
(2.5 µg/ml; LS-B930) (LifeSpan Biosciences, UK), rabbit polyclonal C-
CL10 (4 µg/ml; Orb13568), rabbit polyclonal CCL12 (2 µg/ml;
Orb132384), rabbit polyclonal CCL15 (4 µg/ml; Sc-28388) (Biorbyte,
UK), rabbit anti-human von Willebrand Factor (VWF) (3 µg/ml; A0082)
and mouse anti-human VWF (4 µg/ml; M0616) (Dakocytomation, UK).
Isotype matched control antibodies were used throughout. Sections
were then rinsed for in PBS for 3 × 5 min prior to incubation for 45 min
in the secondary antibodies which were anti-mouse, rabbit or goat
Alexa ﬂuor 488 (3.3 µg/ml) and anti-mouse/rabbit/goat Alexa ﬂuor
594 (6.6 µg/ml) in PBS (Invitrogen, UK). (for speciﬁc dilution and
blocking buﬀers used for each antibody please refer to supplementary
data table).
2.2.2. Sampling of tissue sections and calculations
For each individual the ﬁrst 15 blood vessels positive for VWF in 4
ﬁelds of view per section were counted randomly and blind (magniﬁ-
cation X20), any of those vessels also positive for the chemokine under
investigation were then counted.
From this the percentage of chemokine positive vessels was calcu-
lated as follows: number of VWF and chemokine dual positive vessels ÷
number of VWF positive vessels × 100. Means were then calculated
with standard errors. Immunoﬂuorescence was visualised on a light
microscope (Olympus IX51) and yellow staining indicated strong co-
localisation between VWF and the chemokine.
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2.3. ELISA
ELISA was performed using CCL7, CCL14, CCL16 and CCL22 DuoSet
ELISA kits (R & D Systems, UK); wash buﬀer, reagent diluent, substrate
solution and stop solution (all R & D Systems) were used throughout
according to the manufacturer’s instructions. Titrations were performed
to establish the optimal working concentrations for both the serum and
SF samples. Sample standards were run for each experiment.
2.4. Statistical analysis
For analysis of immunoﬂuorescence Student’s t-test was used to
compare the mean percentage (± SE) of VWF+ vessels stained with
the four most highly presented novel chemokines in RA and non-RA
synovia. For analysis of ELISA data, Kruskal-Wallis ANOVA followed by
Dunn’s multiple comparison test was used to analyse diﬀerences in
median sera and SF levels for each chemokine between RA and OA.
Spearman rank correlations were performed to assess sera and SF
chemokine levels with the range of clinical variables mentioned pre-
viously. Statistical analysis was performed using NCSS software (NCSS,
Kaysville, UT, USA) with p < 0.05 being deemed as signiﬁcant.
3. Results
3.1. Abundant chemokines identiﬁed as novel in RA synovial ECs
The chemokines CCL7, CCL14, CCL16 and CCL22 were identiﬁed as
abundant in RA ECs for the ﬁrst time. To further assess the importance
of these chemokines in RA they were also analysed in non-RA synovial
tissue (Table 1, Figs. 1 and 2).
CCL7: CCL7 was observed throughout the RA synovium on vessel
ECs as indicated by white arrows (Fig. 1A–C), and on stromal cells
which appeared in many cases to be cells resembling ﬁbroblasts. A high
degree of colocalisation between VWF and CCL7 on vessel ECs was
observed (Fig. 1A–C), occurring on 69.3% of vessels in RA. The dif-
ference in CCL7 between RA and non-RA tissue (Fig. 1D–F) was not
signiﬁcant (p= 0.54, Table 1).
CCL14: Very strong staining for colocalisation of CCL14 and VWF
(Fig. 1I) was seen in the RA vessels (at 73.0%) (Table 1). CCL14 blood
vessel staining was present in the non-RA synovium but was markedly
weaker, being present at 28.4% of VWF+ vessels. The chemokine was
shown to be signiﬁcantly increased in RA blood vessels compared to
non-RA (p= 0.0041, Table 1).
CCL16: In RA synovium a high degree of CCL16 staining was seen in
vessels with minimal inﬁltrate staining (Fig. 2A–C). CCL16 was not
signiﬁcantly diﬀerent when RA and non-RA tissue (Fig. 2D–F) were
compared (p= 0.89, Table 1).
CCL22: In the RA synovium CCL22 colocalisation with VWF+
vessels was strongly evident (Fig. 2G–I). In non-RA CCL22 was observed
in VWF+ vessels (Fig. 2J–L) to a lesser degree than in RA synovium.
Further to this, the majority of the staining in the non-RA synovium was
observed in stromal cells in close proximity to large vessels. CCL22 was
signiﬁcantly increased in RA with 60.1% of vessels being positive
compared to 18.7% in non-RA (p= 0.014, Table 1).
For all chemokines no background staining was observed on the
negative control sections treated with isotype matched control anti-
bodies in place of primary antibodies.
3.2. Additional chemokines assessed in RA synovial ECs
The major 4 EC chemokines we concentrated on were CCL7, 14, 16
and 22 (Table 1, Figs. 1 and 2). However in the same samples a further
22 chemokines were observed in RA ECs by dual label immuno-
ﬂuorescence (images not shown) and these are quantiﬁed in Table 2 for
comparison.
CCL1: CCL1 was shown to be present in low abundance on both ECs
and inﬁltrates within the RA joint (Table 2).
CCL2: CCL2 was present in both inﬁltrates and ECs. Particularly
intense EC staining was observed in regions of more diﬀuse leukocyte
inﬁltration, with weaker EC staining seen in regions of lymphoid fol-
licles and more dense inﬁltration.
CCL3: CCL3 was observed in RA ECs and predominantly seen on the
basement membrane.
CCL4: CCL4 was shown to be well represented on RA ECs
(62.3%±11.0) with positive cells also observed in the inﬁltrate. CCL4
staining was also observed within EC vessel walls in non-RA synovial
tissue (49.2%±16.0) but was not statistically signiﬁcant compared to
RA (p= 0.49).
CCL5: CCL5 staining was evident throughout the synovium, in-
cluding EC basement membrane, luminal EC surface, and on inﬁltrating
cells including those within lymphoid aggregates.
CCL8: CCL8 was present throughout the RA synovium at 64.1%
(±7.4) and the non-RA synovium at 25.6% (± 17.0) (p= 0.04).
Strong colocalisation was seen in VWF+ vessels, while CCL8+ staining
of other cell types appeared to be primarily in ﬁbroblast-like cells. .
CCL10: CCL10 was shown to be colocalised on VWF+ vessels and
also present on inﬁltrated cells, with particularly intense staining at the
synovial intima.
CCL11: A number of small VWF+ vessels showed weak staining for
CCL11. However, the staining was more intense in larger vessels where
leukocyte staining was also present.
CCL12: CCL12 stained sparsely and very weakly in VWF+ vessels
with a small degree of inﬁltrate staining also seen.
CCL13: Colocalisation between CCL13 and VWF was observed with
numerous inﬁltrating cells also CCL13+.
CCL15: CCL15 staining was seen in numerous VWF+ vessels with
strong staining in the cells of the intima. Inﬁltrate staining was seen to
be primarily in cells near the vessels or intima.
CCL17: Only weak staining of CCL17 could be found on a relatively
low number of vessel ECs with inﬁltrating cells also being CCL17+.
CCL18: Leukocyte staining was primarily seen to be on cells in close
association with CCL18+ vessels.
CCL19: Colocalisation between CCL19 and VWF was observed in RA
vessels. Inﬁltrating cells were also positive for CCL19 particularly in
lymphoid follicles with their associated ECs. In the non-RA synovium
CCL19 was present, but only on a small number of VWF+ vessels. In RA
the chemokine occurred on the ECs of 80.0% (±4.5) of blood vessels
and only 10.3% (±2.6) of blood vessels in non-RA (p = <0.0001).
CCL20: Very little CCL20 could be found on the vessel ECs but was
identiﬁable in the intimal layer.
CCL21: EC CCL21 was observed throughout the synovium and im-
munoreactivity was noticeable in inﬁltrating cells.
CCL23: A combination of both strongly and weakly positive vessels
was seen in the RA synovium. CCL23+ inﬁltrating cells were also ob-
served which were localised within aggregates.
CCL24: CCL24 was observed to localise to both large and small
vessels. However, more intense staining was seen on small vessels.
Table 1
Most abundant novel chemokines present in VWF positive vessels in RA compared to non-
RA synovia.
Chemokine RA Non-RA p
CCL7 69.3% (± 6.1) 61.9% (± 14.8) p= 0.54
CCL14 73.0% (± 7.0) 28.4% (± 8.2) p= 0.0041***
CCL16 74.1% (± 7.2) 75.3% (± 7.0) p= 0.89
CCL22 60.1% (± 8.1) 18.7% (± 5.7) p= 0.014*
Data show the percentage of VWF positive vessels that were chemokine positive in RA
(n = 8) and non-RA synovia (n = 5). Data are means ± SE, signiﬁcant diﬀerences as
assessed by Student’s t-test are shown.
* p < 0.05
*** p < 0.005.
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CCL25: CCL25 was present primarily on the ECs of larger VWF+
vessels. Where staining occurred on smaller vessels it was seen to be
much weaker.
CCL26: Colocalisation of CCL26 and VWF was observed in a rela-
tively large number of vessels. Inﬁltrate staining was also present
throughout the samples with some areas being particularly intensely
labelled.
CCL27: Immunoreactivity was present in inﬁltrating cells with very
few examples of CCL27 and VWF colocalisation occurring.
CCL28: Colocalisation between CCL28 and VWF was evident with
weaker CCL28 staining observed in smaller vessels. A high degree of
intima staining for CCL28 was observed.
For all chemokines no background staining was observed on the
negative control sections treated with isotype control IgGs instead of
primary antibodies.
3.3. CCL7, CCL14, CCL16 and CCL22 in RA and OA SF and sera
In serum, CCL7 was detected almost solely in RA, being present in
the serum of only one OA (Fig. 3A). In the SF, CCL7 was present in the
majority of RA but no OA patients. Further analysis showed signiﬁcant
diﬀerences between CCL7 levels in the RA and OA SF and OA serum
(p < 0.01).
CCL14 was detected in the serum and SF of RA and OA at com-
paratively high levels (Fig. 3B). The results indicated no signiﬁcant
diﬀerences in CCL14 levels between RA and OA serum or SF.
As with CCL14, CCL16 was detected in both the serum and SF of RA
and OA. However there was a signiﬁcant diﬀerence (p < 0.001) be-
tween CCL16 levels in RA serum compared to RA SF and OA SF
(Fig. 3C). There were no signiﬁcant diﬀerences between RA serum and
OA serum CCL16 levels observed.
CCL22 was detected in the serum and SF of RA and OA (Fig. 3D).
The CCL22 level in the RA serum was shown to be signiﬁcantly higher
than in OA SF (p < 0.05).
3.4. Analysis of correlations in RA SF and serum
Spearman rank correlation analysis followed by the Holm-
Bonferroni test on serum and SF showed a signiﬁcant correlation be-
tween serum levels of CCL7 and CCL16 (R = 0.64, p= 0.016). A highly
signiﬁcant correlation between SF CCL7 levels and anti-citrullinated
antibody (anti-CCP) levels was also observed (R = 0.93, p= 0.001).
Fig. 1. CCL7 and CCL14 in RA and non-RA synovium. For RA CCL7 (A, B, C) and CCL14 (G, H, I), non-RA CCL7 (D, E, F) and CCL14 (J, K, L) chemokines are shown in red with von-
Willebrand factor (VWF) in green and DAPI in blue, with merged images to illustrate colocalisation. The white box in Image C shows an enlargement of the vessel indicated by a white
arrow in the same image. Scale bars in A-F show 200 µm and in G-L 100 µm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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No signiﬁcant correlations were observed between levels of CCCL7,
CCL14, CCL16 or CCL22 and the clinical measures of disease activity,
joint damage or function
4. Discussion
Inﬂammation under normal (non-RA) conditions is a protective
mechanism in response to injury and/or tissue damage whereby leu-
kocytes travel to the site of injury to remove infectious agents and fa-
cilitate tissue repair. The transendothelial migration of leukocytes is
also a major feature in chronic inﬂammation in RA as it is the method
by which leukocytes in the post capillary venules cross from the cir-
culating blood to the site of ‘injury’. This migration across ECs and the
basement membrane into the synovial tissue and SF is mediated via a
range of processes, including the action of chemokines [5].
This study has compared the presence of 26 of the CC-family che-
mokines in RA synovial ECs. The detection of chemokines varied, the
least abundant being CCL27 which was present in 8.3% of RA blood
vessels and the most abundant being CCL19 which was present in 80%.
Of the 26, 19 have not been previously observed in RA ECs (see Tables 1
and 2). However many of them, such as CCL12 [19] and CCL13 [20,21]
have been observed as being in the synovial tissue without analysing
their exact localisation. From the 26 chemokines analysed in this study
CCL4, CCL7, CCL8, CCL14, CCL16, CCL19 and CCL22 were present on
≥60% of vessels, of which CCL7, CCL14, CCL16 and CCL22 had not
previously been identiﬁed as present in RA ECs.
Of the four most abundant novel EC chemokines found by this
study, (CCL7, CCL14, CCL16 and CCL22), CCL14 showed the most
signiﬁcant increase in RA synovial ECs compared to non-RA. This is the
ﬁrst study to show CCL14 to be present in RA ECs and suggests that this
chemokine may play a role in the recruitment of inﬂammatory cells into
the RA synovium as it has been shown to chemoattract monocytes,
eosinophils and T-cells [22].
CCL22 was also signiﬁcantly increased in RA ECs compared to non-
RA (p= 0.014). This relates to earlier work identifying CCL22 ‘scat-
tered throughout’ RA synovium and CCR4, the CCL22 receptor, loca-
lised on ECs [23]. In the current study the increased presence of CCL22
in RA ECs indicates that it may have a role in the recruitment of in-
ﬂammatory cells to the RA synovium such as monocytes and T lym-
phocytes.
Our study showed CCL7 to be highly expressed on RA ECs, however
further examination showed no signiﬁcant diﬀerences between RA and
Fig. 2. CCL16 and CCL22 in RA and non-RA synovium. For RA CCL16 (A, B, C), CCL22 (G, H, I) and non-RA CCL16 (D, E, F), CCL22 (J, K, L) chemokines are shown in red with von-
Willebrand factor (VWF) in green and DAPI in blue, with merged images to illustrate colocalisation. Scale bars in A-C and G-I are 200 µm, and in D-F and J-L 50 µm. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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non-RA. This was also supported by work from a diﬀerent group [20]
who ﬁrst identiﬁed CCL7 in RA tissue and found it to be ‘abundantly
present’ in all arthritis and control groups tested. The presence of CCL7
on stromal cells resembling ﬁbroblasts within the RA tissue is in
agreement with Haringman et al. who showed marked expression by
ﬁbroblast-like synoviocytes (FLS) and macrophages [20].
While CCL16 has been previously identiﬁed in RA tissue [20,24,25]
this is the ﬁrst study to identify its presence in RA ECs. The results
indicate that there are no signiﬁcant diﬀerences between VWF+ ECs in
RA and non-RA tissue and so it may be unlikely that CCL16 plays a
dominant role in the elevated leukocyte traﬃcking into the synovium
seen in RA.
The chemokines CCL4, CCL8 and CCL19 which have not been
quantiﬁed by other studies but have been identiﬁed as present in RA
ECs have also been further examined here. It was established that
CCL19 was the most highly expressed at RA ECs, followed by CCL8 then
CCL4. While CCL4 has been previously identiﬁed in RA ECs [26,27] this
study is the ﬁrst to quantify its presentation in comparison to control
non-RA tissue, where the control tissue is not from another arthritis
type. The amount of CCL4 had previously been established as decreased
in RA SF compared to OA SF [26]; the present study shows that CCL4
does not signiﬁcantly diﬀer in RA compared to non-RA ECs. While CCL4
acts as a chemoattractant for a variety of leukocytes including T-cells
and B-cells [28] as well as monocytes and NK cells [29] the results of
this study indicate that it may not be primarily important in stimulating
the elevated leukocyte recruitment seen in RA.
CCL8 activates and chemoattracts a range of cells, including
monocytes, T-cells, NK cells and ﬁbroblast-like synoviocytes (FLS)
[30,31]. This study showed that the amount of CCL8 is signiﬁcantly
increased in RA ECs compared to non-RA ECs, which is supported by an
earlier study where a signiﬁcant increase of CCL8 in RA ECs was ob-
served, but in comparison to OA ECs [32]. The presence of CCL8+
stromal cells which were ﬁbroblast-like have also been observed in a
previous report [20].
The presence of CCL19 in RA ECs agrees with earlier reports where
CCL19 was established as present at RA ECs [33] and was shown to be
expressed on both lymphatic and vascular ECs in RA [34]. The present
study also suggested more intense CCL19 staining to be present in the
more densely inﬁltrated lymphoid follicle inﬁltrates and ECs. This
supports earlier work which found CCL19 to be expressed in RA tissue
where germinal centres were present, and absent where only diﬀuse
inﬁltrates were found [33]. Our results show that CCL19 was highly up-
regulated on RA ECs compared to non-RA and supports the notion of it
being an important chemokine in lymphocyte recruitment.
The presence of chemokines diﬀerentially expressed in synovial
tissues raised the question of examining their presence in the SF and
sera of RA and OA patients. It is accepted that certain chemokines are
found in the serum and/or SF of arthritis suﬀerers and that the che-
mokine proﬁles in serum and/or SF diﬀer with disease duration and
between diﬀerent arthritides. This may allow for the further identiﬁ-
cation of potential disease markers. For example, SF levels of cytokines
in patients with early RA have been shown to have diﬀering cytokine
proﬁles at diﬀerent disease stages [13,14]. Chemokines found in the SF
of RA patient such as CCL3 and CCL5 have been shown to be upregu-
lated in RA compared to other arthropathies [35,36].
The signiﬁcant correlations between CCL7 levels in RA SF and anti-
CCP antibodies in RA combined with the lack of CCL7 in OA SF suggests
that CCL7 may be a novel marker for RA. The increase in SF CCL7 in RA
may be due to CCL7 generation by the abundant macrophages of the RA
joint [37,38]. Furthermore, the presence of CCL7 in SF at signiﬁcantly
greater concentrations than in serum, indicates that the synovial tissue
may be a primary source of CCL7.
We have shown that there are no signiﬁcant diﬀerences in the
CCL14 SF and serum levels in RA compared to OA. CCL14 has been
shown to be expressed at high concentrations of 10 nM (86,730 pg/ml)
in the plasma of healthy individuals which signiﬁcantly increases up to
80nM (693,840 pg/ml) in patients with renal disease [39]. However, it
is unusual for a chemokine to reach such levels, even in a disease state.
CCL16 was signiﬁcantly higher in RA serum compared to matched
SF, and to OA SF. This suggests that it may be generated remotely,
mainly by other tissues or possibly other joints, rather than by the knee
joints studied here. As with CCL14, CCL16 was shown to be present at
relatively high concentrations. This is lower than chemokines such as
CCL2, but higher than CCL5 in RA [38]. However, there were no sig-
niﬁcant CCL16 increases in RA serum compared to OA serum sug-
gesting it may not be a potential marker in RA. Due to a lack of cor-
relation between serum/SF levels and clinical variables it is unlikely to
be of signiﬁcance as a marker of disease activity or severity. Flytlie et al.
[40] showed increased CCL22 levels in RA compared to OA and healthy
plasma. The current study showed that CCL22 levels were signiﬁcantly
increased in RA serum compared to OA SF with no signiﬁcant corre-
lations with clinical variables evident.
Our data suggest that several chemokines are abundantly present at
the ECs of RA synovium, rather than occurring individually. This sug-
gests potential synergistic eﬀects between the chemokines may promote
disease. Furthermore, synergism has been observed in previous studies
with a range of mechanisms having been put forward to account for this
[41]. As it has been shown that CXCL13 and CCL21 have synergistic
eﬀects in lymphoid tissue production in RA synovitis [42] and more
recently that CCL7 has been shown to synergise with CXCL8 in acute
respiratory distress syndrome to promote neutrophil migration [43].
Thus it is possible that currently unexplored synergistic responses be-
tween CCL14, CCL19 and CCL22 for example and other chemokines are
present in RA ECs.
5. Conclusions
The presence of 26 of the CC-chemokines in RA synovial ECs have
been quantiﬁed and compared. The chemokines CCL7, CCL14, CCL16
and CCL22 were established as being present at RA synovial ECs for the
ﬁrst time. These early results show a signiﬁcant increase of CCL8,
CCL14, CCL19 and CCL22 in RA compared to non-RA synovium and
following further validation may suggest that EC presentation of these
Table 2
Chemokines present at VWF positive vessels in RA synovia.
Chemokine RA
CCL1♣ 11.9% (±4.0)
CCL2 51.5% (±6.9)
CCL3 27.4% (±6.1)
CCL4 62.3% (±11.0)
CCL5 44.9% (±7.6)
CCL8 64.1% (±7.4)
CCL10♣ 52.6% (±10.0)
CCL11♣ 15.8% (±6.3)
CCL12♣ 9.6% (± 3.2)
CCL13♣ 56.6% (±7.0)
CCL15♣ 47.3% (±6.3)
CCL17♣ 17.4% (±10.6)
CCL18♣ 38.0% (±6.4)
CCL19 80.0% (±4.5)
CCL20♣ 18.5% (±2.7)
CCL21 36.1% (±10.4)
CCL23♣ 37.7% (±4.5)
CCL24♣ 28.8% (±4.6)
CCL25♣ 28.2% (±4.5)
CCL26♣ 59.8% (±7.5)
CCL27♣ 8.3% (± 1.2)
CCL28♣ 40.9% (±6.8)
Data show the percentage of VWF positive vessels in RA sy-
novia (n = 8) that were also chemokine positive.
♣ Indicates novel identiﬁcation on synovial ECs at the time
of writing. Data are means ± SE as a percentage of VWF
positive vessels also stained with the chemokine.
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chemokines could also play a role in the recruitment of inﬂammatory
cells in RA. Further studies are needed to explore the functionality of a
number of these EC chemokines and their potential roles in RA. The
study also indicates that SF CCL7 may be a novel RA disease marker.
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